Michael Birnbaum, Anders Hansen, and Tami Lieberman receive NIH Director’s New Innovator Awards from the NIH Common Fund’s High-Risk, High-Reward Research program.
MIT researchers find blocking the expression of the genes XPA and MK2 enhances the tumor-shrinking effects of platinum-based chemotherapies in p53-mutated cancers.
Funding will support workshops to advance research, development, and translation in emerging areas of socioresilient and sustainable infrastructure, and in ocean environments.